Should You Sell Virpax Pharmaceuticals Inc (VRPX) And Go Away This Year?

Virpax Pharmaceuticals Inc (NASDAQ:VRPX) currently has a daily average trading volume of 7.23M but it saw 6576522 shares traded in last market. With a market cap of 2.65M USD, the company’s current market price of $0.10 came falling about -8.35 while comparing to the previous closing price of $0.11. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.82 and as low as $0.10. In the recent trading on the day, stock has struck highest price mark of $0.095 while lowest mark touched by it was $0.1028.

Taking a look at 20-day trading activity of Virpax Pharmaceuticals Inc (VRPX) gives us an average price of $0.1918, while its current price level is -97.93% below from 52-week high level whereas it is -1.09% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.2611 while that of 200 days or SMA-200 reads an average of $0.6196. A closer look into the stock’s movement over the week reveals that its volatility is standing at 12.39% during that period while stretching the period over a month that decreases to 9.95%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 19.29 which implies that the stock is in oversold territory.

Over the week, VRPX’s stock price is moving -43.88% down while it is -63.99% when we observe its performance for the past one month. Year-to-date it is -73.70% down and over the past year, the stock is showing a downside performance of -97.32%.

The company is expected to be releasing its next quarterly report on 2025-Mar-02, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.

Currently, Virpax Pharmaceuticals Inc’s total number of outstanding shares is 26.56M with 0.96% of that held by the insiders while 0.41% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at -2364.82%. Stock’s beta reads 1.22. Its return on asset (ROA) is -215.80% on average.